CTKB
Cytek Biosciences, Inc.
$4.09
-5.54%
$528.2M
No data for this timeframe.
Vol
Market Cap$528.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (70%)
Inst. Holders8 funds
Inst. Value$61.6M
Inst. Activity3 buys / 1 sells
SEC Reports2
Recent Activity
Jun 2, 2026
other
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
At CYTO 2026, Cytek will showcase its cell analysis solutions, including the public debut of a new 7
Jun 2, 2026
SEC
Cytek Biosciences disclosed the resignation of Philippe Busque, Ph.D., Senior Vice President of Global Sales and Service
8-K — Impact 3/10
May 18, 2026
Insider
Barnett Valerie sold 2,454 shares
CHIEF LEGAL OFFICER @ $0.00 ($0.00)
May 18, 2026
Insider
Barnett Valerie sold 881 shares
CHIEF LEGAL OFFICER @ $3.55 ($3.1K)
May 18, 2026
Insider
Barnett Valerie sold 2,454 shares
CHIEF LEGAL OFFICER @ $0.00 ($0.00)
Apr 28, 2026
SEC
Cytek Biosciences filed additional definitive proxy soliciting materials (DEFA14A) on April 28, 2026. The filing is a ro
DEFA14A — Impact 2/10
Inst.
BANK OF AMERICA CORP — DOUBLED
856,161 shares ($4.3M)
Inst.
FMR LLC — ADD
234,072 shares ($1.2M)
Price Targets
$5.69
+39.1% upside
Strong Buy
Current $4.09
Low $4.75
Median $5.25
High $7.50
4 analysts
$4.75
$7.50
Analyst Ratings
3Strong Buy
4Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Stephens & Co. | MAINTAIN | Overweight → Overweight |
| May 12, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight → Equal-Weight |
| Jan 8, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.01 ▲ +75.0% | $-0.01 — $-0.01 | -40% YoY | 1 |
| Next Q | $0.01 ▲ +166.7% | $0.01 — $0.01 | 3433% YoY | 1 |
| Current FY | $-0.04 ▲ +52.9% | $-0.04 — $-0.04 | 87% YoY | 1 |
| Next FY | $0.19 ▲ +322.2% | $0.19 — $0.19 | 575% YoY | 1 |
Latest Reports
NEUTRAL
8-K
3/10
Cytek Biosciences disclosed the resignation of Philippe Busque, Ph.D., Senior Vice President of Global Sales and Service
Jun 2, 2026
NEUTRAL
DEFA14A
2/10
Cytek Biosciences filed additional definitive proxy soliciting materials (DEFA14A) on April 28, 2026. The filing is a ro
Apr 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $37.8M | — |
| MORGAN STANLEY | $8.6M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $5.5M | NEW |
| BANK OF AMERICA CORP | $4.3M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $3.4M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Barnett Valerie | M | $0.00 |
| May 18, 2026 | Barnett Valerie | F | $3.1K |
| May 18, 2026 | Barnett Valerie | M | $0.00 |
| May 18, 2026 | McCombe William | M | $0.00 |
| May 18, 2026 | McCombe William | F | $8.1K |
8 institutional holders with $61.6M total value (12,198,941 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 7,475,477 | $37.8M | 61.3% | — |
| 2 | MORGAN STANLEY | 1,700,985 | $8.6M | 13.9% | ADD +27.2% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,094,539 | $5.5M | 9.0% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 856,161 | $4.3M | 7.0% | DOUBLED +403.2% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 675,000 | $3.4M | 5.5% | TRIM -25.2% |
| 6 | FMR LLC | 234,072 | $1.2M | 1.9% | ADD +29.5% |
| 7 | WELLS FARGO & COMPANY/MN | 132,675 | $670.0K | 1.1% | ADD +46.8% |
| 8 | TWO SIGMA INVESTMENTS, LP | 30,032 | $151.7K | 0.2% | NEAR_EXIT -82.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 170,160 | 856,161 | +403.2% | $4.3M | 2025-Q4 |
| FMR LLC | ADD | 180,786 | 234,072 | +29.5% | $1.2M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 90,401 | 132,675 | +46.8% | $670.0K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 175,759 | 30,032 | -82.9% | $151.7K | 2025-Q4 |
| MORGAN STANLEY | ADD | 1,150,121 | 1,463,141 | +27.2% | $5.1M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,063,139 | 795,544 | -25.2% | $2.8M | 2025-Q3 |
| UBS Group AG | TRIM | 632,052 | 468,689 | -25.8% | $1.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 175,759 | — | $609.9K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 91,612 | 170,160 | +85.7% | $590.5K | 2025-Q3 |
| MORGAN STANLEY | ADD | 745,477 | 1,150,121 | +54.3% | $3.9M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 687,600 | 1,063,139 | +54.6% | $3.6M | 2025-Q2 |
| FMR LLC | TRIM | 717,160 | 205,741 | -71.3% | $699.5K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 332,121 | 91,612 | -72.4% | $311.5K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 1,089,461 | 745,477 | -31.6% | $3.0M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 462,600 | 687,600 | +48.6% | $2.8M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 202,140 | 608,017 | +200.8% | $2.4M | 2025-Q1 |
| UBS Group AG | DOUBLED | 18,944 | 665,733 | +3414.2% | $4.3M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 211,600 | 462,600 | +118.6% | $3.0M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 270,972 | 202,140 | -25.4% | $1.3M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 55,724 | 71,240 | +27.8% | $462.3K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,030,962 | — | $5.7M | 2024-Q3 |
7 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | M | 2,454 | $0.00 | $0.00 |
| May 18, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | F | 881 | $3.55 | $3.1K |
| May 18, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | M | 2,454 | $0.00 | $0.00 |
| May 18, 2026 | McCombe William D. | Chief Financial Officer | M | 6,320 | $0.00 | $0.00 |
| May 18, 2026 | McCombe William D. | Chief Financial Officer | F | 2,268 | $3.55 | $8.1K |
| May 18, 2026 | McCombe William D. | Chief Financial Officer | M | 6,320 | $0.00 | $0.00 |
| May 18, 2026 | Jiang Wenbin | PRESIDENT AND CEO | M | 7,854 | $0.00 | $0.00 |
| May 18, 2026 | Jiang Wenbin | PRESIDENT AND CEO | F | 1,913 | $3.55 | $6.8K |
| May 18, 2026 | Jiang Wenbin | PRESIDENT AND CEO | M | 7,854 | $0.00 | $0.00 |
| May 18, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | M | 1,024 | $0.00 | $0.00 |
| May 18, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | F | 263 | $3.55 | $933.65 |
| May 18, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | M | 1,024 | $0.00 | $0.00 |
| May 18, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | M | 4,908 | $0.00 | $0.00 |
| May 18, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | F | 1,224 | $3.55 | $4.3K |
| May 18, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | M | 4,908 | $0.00 | $0.00 |
| May 18, 2026 | Chin Richard | Director | M | 6,107 | $0.00 | $0.00 |
| May 18, 2026 | Chin Richard | Director | M | 6,107 | $0.00 | $0.00 |
| May 18, 2026 | Holder Michael | Director | M | 1,454 | $0.00 | $0.00 |
| May 18, 2026 | Holder Michael | Director | M | 1,454 | $0.00 | $0.00 |
| Mar 13, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | G | 1,176,000 | $0.00 | $0.00 |
| Mar 10, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | A | 120,688 | $0.00 | $0.00 |
| Mar 10, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | A | 227,535 | $0.00 | $0.00 |
| Mar 10, 2026 | McCombe William D. | Chief Financial Officer | F | 2,603 | $4.23 | $11.0K |
| Mar 10, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | M | 9,817 | $0.00 | $0.00 |
| Mar 10, 2026 | Jiang Wenbin | PRESIDENT AND CEO | M | 15,708 | $0.00 | $0.00 |
| Mar 10, 2026 | McCombe William D. | Chief Financial Officer | M | 6,320 | $0.00 | $0.00 |
| Mar 10, 2026 | Jiang Wenbin | PRESIDENT AND CEO | M | 15,708 | $0.00 | $0.00 |
| Mar 10, 2026 | Jiang Wenbin | PRESIDENT AND CEO | F | 3,825 | $4.23 | $16.2K |
| Mar 10, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | F | 1,761 | $4.23 | $7.4K |
| Mar 10, 2026 | Jiang Wenbin | PRESIDENT AND CEO | A | 485,545 | $0.00 | $0.00 |
| Mar 10, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | F | 635 | $4.23 | $2.7K |
| Mar 10, 2026 | Chin Richard | Director | M | 6,107 | $0.00 | $0.00 |
| Mar 10, 2026 | Chin Richard | Director | M | 6,107 | $0.00 | $0.00 |
| Mar 10, 2026 | Holder Michael | Director | M | 2,908 | $0.00 | $0.00 |
| Mar 10, 2026 | Holder Michael | Director | M | 2,908 | $0.00 | $0.00 |
| Mar 10, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | A | 70,665 | $0.00 | $0.00 |
| Mar 10, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | A | 133,226 | $0.00 | $0.00 |
| Mar 10, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | M | 2,049 | $0.00 | $0.00 |
| Mar 10, 2026 | Busque Philippe | SVP, GLOBAL SALES AND SERVICES | M | 2,049 | $0.00 | $0.00 |
| Mar 10, 2026 | McCombe William D. | Chief Financial Officer | A | 256,790 | $0.00 | $0.00 |
| Mar 10, 2026 | McCombe William D. | Chief Financial Officer | M | 6,320 | $0.00 | $0.00 |
| Mar 10, 2026 | McCombe William D. | Chief Financial Officer | A | 136,205 | $0.00 | $0.00 |
| Mar 10, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | M | 9,817 | $0.00 | $0.00 |
| Mar 10, 2026 | Yan Ming | CHIEF TECHNOLOGY OFFICER | F | 3,047 | $4.23 | $12.9K |
| Mar 10, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | A | 226,453 | $0.00 | $0.00 |
| Mar 10, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | M | 4,908 | $0.00 | $0.00 |
| Mar 10, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | A | 120,114 | $0.00 | $0.00 |
| Mar 10, 2026 | Barnett Valerie | CHIEF LEGAL OFFICER | M | 4,908 | $0.00 | $0.00 |
| Mar 10, 2026 | Jiang Wenbin | PRESIDENT AND CEO | A | 915,407 | $0.00 | $0.00 |
| Feb 18, 2026 | Jiang Wenbin | PRESIDENT AND CEO | M | 4,514 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 2.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (70% buy). Based on 10 analysts: 3 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.69 mean target
+39.1% upside
Strong Buy (3.00)
$4.75 Low
$7.50 High
| Metric | Value |
|---|---|
| Current Price | $4.09 |
| Target Low | $4.75 |
| Target Mean | $5.69 |
| Target Median | $5.25 |
| Target High | $7.50 |
| # Analysts | 4 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.01 | $-0.01 | $-0.01 | -40.5% | +75.0% | 0↑ 1↓ | $0.0B | 6.6% | 1 |
| Next Q 2026-09-30 |
$0.01 | $0.01 | $0.01 | 3433.3% | +166.7% | 0↑ 1↓ | $0.1B | 5.5% | 1 |
| Current FY 2026-12-31 |
$-0.04 | $-0.04 | $-0.04 | 87.2% | +52.9% | — | $0.2B | 3.6% | 1 |
| Next FY 2027-12-31 |
$0.19 | $0.19 | $0.19 | 575.0% | +322.2% | 0↑ 1↓ | $0.2B | 6.6% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.010 | |
| 7d ago | $-0.050 | +0.040 |
| 30d ago | $-0.040 | +0.030 |
| 60d ago | $-0.040 | +0.030 |
| 90d ago | $-0.015 | +0.005 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Stephens & Co. | MAINTAIN | Overweight | Overweight |
| May 12, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Jan 8, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| May 1, 2026 | 3 | 4 | 3 | 0 | 0 | 70% | |
| Apr 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Mar 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% | |
| Feb 1, 2026 | 2 | 4 | 4 | 0 | 0 | 60% | |
| Jan 1, 2026 | 3 | 4 | 4 | 0 | 0 | 64% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
other
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
At CYTO 2026, Cytek will showcase its cell analysis solutions, including the public debut of a new 7-laser Cytek Borealis full spectrum flow cytometer
May 15, 2026
short_volume
Short Volume: CTKB — 55.2% short (0.3M / 0.5M)
Short: 300,597 | Exempt: 16,745 | TRF Vol: 544,400 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
CTKB Q1 2026 Earnings After Market Close — 2026-05-07
Mar 9, 2026
other
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences celebrates one year of operations at its Singapore facility, which has enhanced Cytek’s manufacturing capacity and regional service.
Feb 26, 2026
earnings_calendar
CTKB Q4 2025 Earnings After Market Close — 2026-02-26